Phase 2 N=22 Efficacy of an Intranasal Testosterone Product
Hypogonadism
Primary: Cmax of Serum Testosterone — 830; 1050; 883 ng/dL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 PPARγ Agonist Treatment for Cocaine Dependence
Cocaine Use Disorder · Alcohol Use Disorder
Primary: Craving as Assessed by the Brief Substance Craving Scale (BSCS) — 5.57; 6.23; 5.00; 5.08 units on a scale
Phase 2 N=57 Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma
Recurrent Hodgkin Lymphoma · Refractory Hodgkin Lymphoma
Primary: Overall Response Rate Among Patients With Salvage Brentuximab Vedotin (BV) — 75.0 percentage of participants with response
Phase 2 N=50 Rollover Study Protocol for Pediatric Patients in South Africa for Continued Access to Emtricitabine
HIV-1 Infection
Primary: Number of Participants Who Had Access to, and Received the Intervention — 50 Participants
Phase 2 N=16 A Pilot Study of Minocycline in Intracerebral Hemorrhage Patients
Intracerebral Hemorrhage
Primary: Modified Rankin Scale — 3.5; 3.7 units on a scale
Phase 2 N=201 A Study in Older Participants Who Have Fallen and Have Muscle Weakness
Muscle Weakness
Primary: Change From Baseline to 24 Week Endpoint in Appendicular Lean Body Mass (aLBM) — 0.303; -0.123 kilograms (kg) — p=<0.001
Phase 2 N=182 An Open Label Extension Study in Participants With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Number of Participants Who Had Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 38; 95; 1; 4 Participants
Phase 2 N=227 A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Depressive Disorder, Major
Primary: Change From Baseline to 8 Weeks in Montgomery-Asberg Depression Rating Scale (MADRS) — -8.13; -5.76 units on a scale
Phase 2 N=39 Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder
Opioid Use Disorder
Primary: Opioid Blockade Following Administration of Hydromorphone Challenge As Measured Using the Subjective Opioid Effects Rating for the Question "Do You Like the Drug?"…
Phase 2 N=32 Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
Colorectal Cancer · Liver Neoplasms
Primary: Incidence of Adverse Events and Dose Limiting Adverse Events — 0; 69; 47; 44 percentage of participants
Phase 2 N=263 A Study of LY2409021 in Patients With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change From Baseline to 24 Week Endpoint in Hemoglobin A1c (HbA1c) — -0.15; -0.45; -0.78; -0.92 percentage of Hemoglobin A1c (HbA1c) — p=0.094
Phase 2 N=87 A Study for Participants With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Mean Change in Glycosylated Hemoglobin A1c (HbA1c) — 0.11; -0.83; -0.65; -0.66 percentage of HbA1c — p=0.0296
Phase 2 N=40 Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants Who Discontinued Study Treatment During the Induction Period Due to Treatment Emergent Adverse Events (TEAEs). — 27 Percentage of Participants
Phase 2 N=24 Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Lung Cancer
Primary: 6 Month Progression-Free Survival — 69 percentage of participants
Phase 2 N=24 Treatment of Anxiety and Anorexia Nervosa in Adolescents
Anxiety · Anorexia Nervosa
Primary: Medication Side Effects Score — 9.5; 6.2; 6.4; 4.1 Score on a scale